103030-10-0

Basic information

• Product Name: Methyl2,3-dioxoindoline-7-carboxylate
• Synonyms: Methyl2,3-dioxoindoline-7-carboxylate;2,3-Dioxo-2,3-dihydro-1H-indole-7-carboxylic acid methyl ester;7-Methoxycarbonylisatin;Methyl 2,3-dioxo-2,3-dihydro-1H-indole-7-carboxylate
• CAS NO: 103030-10-0
• Molecular Formula: C₁₀H₇NO₄
• Molecular Weight: 205.16688
• EINECS: 1533716-785-6
• Mol File: 103030-10-0.mol

Chemical Properties

• Melting Point: 280 °C
• Appearance: /
• Density: 1.410
• Refractive Index: 1.592
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 8.93±0.20(Predicted)
• CAS DataBase Reference: Methyl2,3-dioxoindoline-7-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl2,3-dioxoindoline-7-carboxylate(103030-10-0)
• EPA Substance Registry System: Methyl2,3-dioxoindoline-7-carboxylate(103030-10-0)

Safety Data

• Hazardous Substances Data: 103030-10-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
Methyl 2,3-dioxoindoline-7-carboxylate is used as a key building block in the pharmaceutical industry for the synthesis of various drugs and organic compounds. Its versatile reactivity and ability to create complex structures contribute to the development of new and innovative medications.
Used in Organic Chemistry Research:
In the field of organic chemistry, Methyl 2,3-dioxoindoline-7-carboxylate is utilized as a valuable research compound. Its unique properties and potential for creating complex structures make it an essential tool for exploring new chemical reactions and mechanisms.
Used in Medicinal Chemistry:
Methyl 2,3-dioxoindoline-7-carboxylate is employed in medicinal chemistry as a potential candidate for the development of new therapeutic agents. Its biological activity and potential medicinal properties are being studied to identify its potential applications in treating various diseases and conditions.
Used in Chemical Education:
In educational settings, Methyl 2,3-dioxoindoline-7-carboxylate serves as an important teaching aid in chemistry courses. It helps students understand the principles of organic synthesis, reactivity, and the formation of complex structures, providing a practical example of these concepts in action.

InChI:InChI=1/C10H7NO4/c1-15-10(14)6-4-2-3-5-7(6)11-9(13)8(5)12/h2-4H,1H3,(H,11,12,13)

Upstream product

• 67-56-1 methanol 
• 25128-35-2 isatin-7-carboxylic acid 
• 74-88-4 methyl iodide 
• 63016-87-5 methyl 2-{[(hydroxyimino)acetyl]amino}benzoate 
• 134-20-3 2-carbomethoxyaniline 

Downstream Products

• 25128-35-2 isatin-7-carboxylic acid 
• 253120-47-7 2-amino-3-(methoxycarbonyl)benzoic acid 
• 31327-97-6 acridine-4-carboxylic acid 
• 610-51-5 4-methyl-acridine 
• 253120-49-9 methyl 2-amino-3-formylbenzoate 
• 253120-48-8 methyl 2-amino-3-(hydroxymethyl)benzoate 
• 128715-84-4 3-hydroxy-8-carboxy-2(1H)-quinolinone 
• 380427-39-4 methyl oxindole-7-carboxylate 
• 1491155-34-0 methyl 3-hydroxy-3-(4-methoxyphenyl)-2-oxindoline-7-carboxylate 
• 1491155-54-4 methyl 3-(5-tert-butyl-2-hydroxyphenyl)-3-(4-methoxyphenyl)-2-oxoindoline-7-carboxylate 
• 1491155-55-5 methyl 3-{5-tert-butyl-2-[2-(morpholin-4-yl)ethoxy]phenyl}-3-(4-methoxyphenyl)-2-oxoindoline-7-carboxylate 
• 1332493-26-1 methyl 2-amino-3-aminocarbonylbenzoate 

Relevant articles and documents

A preparation of methyl 2-amino-3-formylbenzoate and its use in Friedlander synthesis

The title compound has been prepared in four steps from methyl isatin-7- carboxylate. Condensations with 1-indanone and analogs gave 11H-indeno[1,2- b]quinoline-6-carboxylic acids, and with cyclohexanones gave acridine-4- carboxylic acids.

3-3-DI-SUBSTITUTED-OXINDOLES AS INHIBITORS OF TRANSLATION INITIATION

Compositions and methods for inhibiting translation are provided. Compositions, methods and kits for treating (1) cellular proliferative disorders, (2) non-proliferative, degenerative disorders, (3) viral infections, and/or (4) disorders associated with viral infections, using diaryloxindole compounds are described.

Synthesis and SAR study of novel 3,3-diphenyl-1,3-dihydroindol-2-one derivatives as potent eIF2·GTP·Met-tRNAiMet ternary complex inhibitors

The growing recognition of inhibition of translation initiation as a new and promising paradigm for mechanism-based anti-cancer therapeutics is driving the development of potent, specific, and druggable inhibitors. The 3,3-diaryloxindoles were recently reported as potential inhibitors of the eIF2·GTP·Met-tRNAiMet ternary complex assembly and 3-{5-tert-butyl-2-hydroxyphenyl}-3-phenyl-1,3-dihydro-2H-indol-2- one #1181 was identified as the prototypic agent of this chemotype. Herein, we report our continuous effort to further develop this chemotype by exploring the structural latitude toward different polar and hydrophobic substitutions. Many of the novel compounds are more potent than the parent compound in the dual luciferase ternary complex reporter assay, activate downstream effectors of reduced ternary complex abundance, and inhibit cancer cell proliferation in the low μM range. Moreover, some of these compounds are decorated with substituents that are known to endow favorable physicochemical properties and as such are good candidates for evaluation in animal models of human cancer.

QUINAZOLINE DERIVATIVES AS ANTIVIRAL AGENTS

The present invention relates to the use of quinazoline derivatives of formula (I) wherein A, B, R1, R2, R3 and R4 are defined herein, and pharmaceutically acceptable salts thereof, for the treatment or preventi